GLP-1 is a hormone and neuropeptide that inhibits the appetite, reducing eating behaviors and promoting satiety
this may constitute a protocol deviation requiring formal documentation and reporting Do not source retatrutide outside of an approved clinical trial it is not currently licensed for use in the UK, and obtaining it through unofficial channels carries significant safety and legal risks Consult the MHRA website (www.gov.uk/mhra) for the latest information on the regulatory status of retatrutide in the UK Once retatrutide receives regulatory approval, an official SmPC will be published, providing definitive storage guidance for both healthcare professionals and patients
ALSO CONTAINS: Deionized water, alcohol (preservative), potassium hydroxide
serious risks include pancreatitis, gallbladder disease, and hypoglycaemia when combined with certain diabetes medicines
For most injectable GLP-1 receptor agonists (such as semaglutide injections, dulaglutide, and liraglutide), food has minimal impact on drug absorption because the medication is delivered directly into subcutaneous tissue and absorbed into the systemic circulation independently of the gastrointestinal tract
